E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Achondroplasia (ACH) in prepubertal children |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 25.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000452 |
E.1.2 | Term | Achondroplasia |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate efficacy of TransCon CNP on annualized growth velocity (AGV) |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate efficacy of TransCon CNP on height Z-score
• To evaluate safety and tolerability of TransCon CNP
• To evaluate pharmacokinetic properties of TransCon CNP
• To assess potential immunogenic response to TransCon CNP
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Participants are eligible to be included in the trial only if all of the following criteria apply: 1. Written, signed informed consent of the parent(s) or legal guardian(s) of the participant, and as required by the institutional review board/human research ethics committee/independent ethics committee (IRB/HREC/IEC). 2. Male or female, between 2 and 11 years of age (inclusive) at the time of Screening. 3. Clinical diagnosis of ACH with documented genetic confirmation available. 4. Able to stand without assistance. 5. Parent(s)/legal guardian(s) willing and able to administer weekly SC injections of IMP and to follow the protocol. 6. At least six months of growth and disease history from ACHieve (TCC-NHS-01) trial or comparable growth and disease history available from medical records (pending confirmation by Medical Monitor). 7. Considered eligible based on the medical history, physical examination, and the results of vital signs, ECG and clinical laboratory tests performed during the Screening period. |
|
E.4 | Principal exclusion criteria |
Participants are excluded from the trial if any of the following criteria apply: 1. Participation (i.e., signed informed consent) in any interventional clinical trial before within 3 months prior to screening. 2. Closed epiphysis. 3. Known or suspected hypersensitivity to the IMP or related products (trehalose, tris[hydroxymethyl]aminomethane, succinate, and mPEG). 4. Have a growth disorder or medical condition other than ACH that results in short stature or abnormal growth such as severe ACH with developmental delay and acanthosis nigricans (SADDAN), hypochondroplasia, growth hormone deficiency, Turner syndrome, pseudoachondroplasia, inflammatory bowel disease, celiac disease, hypothyroidism, hyperthyroidism, pre-diabetes, or diabetes mellitus. 5. Have received any dose of prescription medications and IMP or surgical intervention intended to affect stature, growth, or body proportionality at any time. 6. Requires, or anticipated to require, chronic (> 4 weeks) or repeated treatment (more than twice/year and >3 weeks/year) with systemic corticosteroids during participation in the trial. Chronic use of high-dose inhaled corticosteroids is not allowed. 7. Known history of presence of injury or disease of the growth plate(s), other than ACH, that affects growth potential of long bones. 8. Known history of any bone-related surgery affecting growth potential of long bones, such as: • Orthopedic reconstructive surgery for bone lengthening (e.g., procedures for leg bowing such as 8-plate are not exclusionary). • Cervicomedullary decompression surgery without anticipated need for repeat decompression during the time of the trial are allowed with minimum of 6 months of bone healing. • Ventriculoperitoneal (VP) shunt and laminectomy with full recovery are allowed with minimum of 6 months of bone healing. • Bone fracture within 6 months prior to screening (within 2 months for fracture of digits and buckle fractures). 9. Clinically significant findings at Screening, such as: • Expected to require surgical intervention during participation in the trial. Common surgeries, such as insertion of grommets, adenoidectomy, tonsillectomy, or myringotomy tube placement, are permitted. • Severe untreated sleep apnea or newly initiated sleep apnea treatment (e.g., Continuous Positive Airway Pressure [CPAP] in the previous 2 months prior to Screening. • Musculoskeletal disease, such as Salter-Harris fractures or clinical and/or radiographic evidence of severe hip pathology, or • Otherwise, are considered by the Investigator and Medical Monitor to make a participant unfit to receive trial treatment or undergo trial related procedures. 10. Have evidence at Screening that are consistent with severe cervicomedullary junction compression based on clinical and/or radiologic findings that indicate immediate surgical intervention is required. 11. Have a clinically significant finding or arrhythmia as determined by the investigator in consultation with the medical monitor that indicates abnormal cardiac function or conduction that includes, but is not exclusive to: • Repaired or unrepaired coarctation. • Moderate or greater complexity congenital heart disease including tetralogy of Fallot, Atrioventricular septal defects, truncus arteriosus, total anomalous pulmonary venous return, double outlet right ventricle, or single ventricle heart disease. 12. QTcF ≥ 450 msec at the Screening Visit. 13. Known history or presence of condition that impacts hemodynamic stability (such as autonomic dysfunction and orthostatic intolerance). 14. Known history or presence of the following: • Chronic anemia (iron deficiency anemia that is resolved or adequately treated in the Investigator’s opinion is allowed). • Chronic renal insufficiency (GFR <60 mL/min/1.73 m2 for >3 months). • Chronic or recurrent illness that can affect hydration or volume status, including conditions associated with decreased nutritional intake or increased volume loss. 15. Known history or presence of malignant disease. 16. Participant with serum 25-hydroxy-vitamin D (25OHD) levels of <30 nmol/L (<12 ng/mL) at Screening Visit will be excluded. Participants with 25OHD levels between 30-50 nmol/L (12-20 ng/mL) can be randomized provided treatment with Vitamin D supplementation is initiated. 17. Any disease or condition that, in the opinion of the Investigator, may make the participant unlikely to fully complete the trial, may confound interpretation of trial results, or may present undue risk from receiving trial treatment. This could include family situations, complications or manifestations, or medications that might impact safety or be considered confounding. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Annualized growth velocity (AGV) at Week 52 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Annualized growth velocity (AGV) will be evaluated at Week 52 |
|
E.5.2 | Secondary end point(s) |
• Change from baseline in height Z-score at Week 52
• Incidence of TEAEs and safety assessments (safety labs, vital signs, physical examination, 12-lead ECG, and radiographic assessments)
• Plasma concentration of Total, Free CNP and mPEG
• Detection and characterisation of ADAs
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• Change from baseline in height Z-score will be evaluated at week 52
• Incidence of TEAEs will be evaluated at each visit and safety assessments (safety labs, vital signs, physical examination, 12-lead ECG, and radiographic assessments) will be evaluated, dependant on procedure, at screening and weeks 0, 4, 12, 26, 39, 52, 56, 64, 78, 91, 104 and 109
• Plasma concentration of Total, Free CNP and mPEG will be evaluted at weeks 4, 12, 26, 39, 52, 56, 64, 78, 91 and 104
• Detection and characterisation of ADAs will be evaluated at weeks 0, 4, 12, 26, 39, 52, 56, 64, 78, 91, 104 and 109 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Randomised period followed by open label extension |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 3 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
New Zealand |
Australia |
Canada |
United Kingdom |
United States |
Denmark |
Ireland |
Spain |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |